{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:42:52Z","timestamp":1792190572469,"version":"4.4.0"},"reference-count":37,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2026,2,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid-induced neurotoxicity (OIN) is a significant complication in palliative care, presenting with symptoms of hypersomnolence, hallucinations, cognitive dysfunction (including delirium), myoclonus and hyperalgesia. Due to limited research studies, a consensus on recognising these clinical manifestations is yet to be reached, complicating both early diagnosis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This rapid review aims to synthesise current evidence on the prevalence, clinical manifestations, risk factors and management strategies of OIN in the palliative care setting to enhance clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic search of Medline, Embase and the Cochrane Central Database, complemented by supplementary searches in ten palliative care journals. Studies with five or more palliative care patients were included, excluding those involving minors, animal models or substance misuse. Data were extracted, cross-checked and synthesised narratively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 studies met the inclusion criteria. Prevalence of OIN varied widely from 6.4% to 38%, with common symptoms including delirium, myoclonus and hyperalgesia. Identified risk factors included age, renal and liver dysfunction, high opioid doses and concurrent use of specific medications. Opioid rotation and dose reduction emerged as potential management strategies, though patient responses varied significantly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OIN is under-diagnosed due to symptom overlap with other conditions. While opioid rotation and dose reduction show promise in managing OIN, further research is needed to establish standardised diagnostic criteria and effective treatment protocols. Enhanced clinical awareness and an individualised approach to opioid prescribing are crucial for improving patient outcomes in palliative care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024543988.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2025-006002","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:21:30Z","timestamp":1774372890000},"page":"spcare-2025-006002","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Opioid-induced neurotoxicity in palliative medicine: a rapid review"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-535X","authenticated-orcid":false,"given":"Audrey","family":"Le Bihan","sequence":"first","affiliation":[{"name":"Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9836-9200","authenticated-orcid":false,"given":"Suzannah","family":"Bridge","sequence":"additional","affiliation":[{"name":"University of Oxford Bodleian Health Care Libraries, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Hedges","sequence":"additional","affiliation":[{"name":"Palliative Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026032410201454000_spcare-2025-006002v1.1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.1999.430910.x"},{"key":"2026032410201454000_spcare-2025-006002v1.2","first-page":"241","article-title":"Adverse effects of opioid analgesics from the central nervous system","volume":"15","author":"Wojtasik-Bakalarz","year":"2021","journal-title":"Palliat Med Pract"},{"key":"2026032410201454000_spcare-2025-006002v1.3","doi-asserted-by":"publisher","DOI":"10.1191\/0269216303pm658oa"},{"key":"2026032410201454000_spcare-2025-006002v1.4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpainsymman.2005.02.003","article-title":"Opioid-related musical hallucinations","volume":"29","author":"Davies","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"2026032410201454000_spcare-2025-006002v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.06.029"},{"key":"2026032410201454000_spcare-2025-006002v1.6","first-page":"S70","article-title":"Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids","volume":"61 Suppl 2","author":"Vearrier","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2026032410201454000_spcare-2025-006002v1.7","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.786"},{"key":"2026032410201454000_spcare-2025-006002v1.8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/082585979000600209","article-title":"Inpatient narcotic infusions for patients with cancer pain","volume":"6","author":"Ferris","year":"1990","journal-title":"J Palliat Care"},{"key":"2026032410201454000_spcare-2025-006002v1.9","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1089\/jpm.2018.0169","article-title":"Frequency, Outcomes, and Associated Factors for Opioid-Induced Neurotoxicity in Patients with Advanced Cancer Receiving Opioids in Inpatient Palliative Care","volume":"21","author":"Lim","year":"2018","journal-title":"J Palliat Med"},{"key":"2026032410201454000_spcare-2025-006002v1.10","first-page":"208","article-title":"Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone","volume":"31","author":"Omoto","year":"2023","journal-title":"Support Care Cancer"},{"key":"2026032410201454000_spcare-2025-006002v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.03.001"},{"key":"2026032410201454000_spcare-2025-006002v1.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026032410201454000_spcare-2025-006002v1.13","unstructured":"Le Bihan A , Bridge S , Hedges V . Opioid-induced neurotoxicity in the palliative care population: a rapid review of the current evidence. PROSPERO 2024 CRD4202454398. Available: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42024543988 [Accessed 21 Jun 2024]."},{"key":"2026032410201454000_spcare-2025-006002v1.14","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2004.7.545"},{"key":"2026032410201454000_spcare-2025-006002v1.15","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2011.0103"},{"key":"2026032410201454000_spcare-2025-006002v1.16","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0467"},{"key":"2026032410201454000_spcare-2025-006002v1.17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0269"},{"key":"2026032410201454000_spcare-2025-006002v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(96)00191-1"},{"key":"2026032410201454000_spcare-2025-006002v1.19","first-page":"10","article-title":"Opioid-induced hyperalgesia after rapid titration with intravenous morphine: Switching and re-titration to intravenous methadone","volume":"1","author":"Mercadante","year":"2012","journal-title":"Ann Palliat Med"},{"key":"2026032410201454000_spcare-2025-006002v1.20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.5055\/jom.2012.0129","article-title":"High opioid dosage rapid detoxification of cancer patient in palliative care with the Raffaeli model","volume":"8","author":"Monterubbianesi","year":"2012","journal-title":"J Opioid Manag"},{"key":"2026032410201454000_spcare-2025-006002v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.02.009"},{"key":"2026032410201454000_spcare-2025-006002v1.22","first-page":"2321","article-title":"Opioid switching and variability in response in pain cancer patients","volume":"27","author":"Corli","year":"2019","journal-title":"Support Care Cancer"},{"key":"2026032410201454000_spcare-2025-006002v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(95)90924-C"},{"key":"2026032410201454000_spcare-2025-006002v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00095-5"},{"key":"2026032410201454000_spcare-2025-006002v1.25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/10499091211065171","article-title":"Incidence of Delirium With Different Oral Opioids in Previously Opioid-Naive Patients","volume":"39","author":"Sugiyama","year":"2022","journal-title":"Am J Hosp Palliat Care"},{"key":"2026032410201454000_spcare-2025-006002v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(93)90188-U"},{"key":"2026032410201454000_spcare-2025-006002v1.27","doi-asserted-by":"publisher","DOI":"10.1007\/s005200000153"},{"key":"2026032410201454000_spcare-2025-006002v1.28","doi-asserted-by":"publisher","DOI":"10.1191\/0269216302pm536oa"},{"key":"2026032410201454000_spcare-2025-006002v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20712"},{"key":"2026032410201454000_spcare-2025-006002v1.30","first-page":"1327","article-title":"The role of methadone in cancer-induced bone pain: a retrospective cohort study","volume":"29","author":"Sulistio","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026032410201454000_spcare-2025-006002v1.31","unstructured":"Explanation of the 2011 OCEBM levels of evidence. Available: https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/explanation-of-the-2011-ocebm-levels-of-evidence [Accessed 28 Oct 2024]."},{"key":"2026032410201454000_spcare-2025-006002v1.32","first-page":"547","article-title":"Successful treatment of hydromorphone-induced neurotoxicity and hyperalgesia","volume":"68","author":"Chung","year":"2004","journal-title":"Conn Med"},{"key":"2026032410201454000_spcare-2025-006002v1.33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.acpain.2006.11.001","article-title":"Opioid-induced hyperalgesia\u2014Pathophysiology and clinical relevance","volume":"9","author":"Koppert","year":"2007","journal-title":"Acute Pain"},{"key":"2026032410201454000_spcare-2025-006002v1.34","unstructured":"Charlesworth S , Howard P , Wilcock A , eds. Appendix 2: opioid dose conversion ratios. In: PCF8: palliative care formulary. 8th edn. London: Pharmaceutical Press, 2022."},{"key":"2026032410201454000_spcare-2025-006002v1.35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy152"},{"key":"2026032410201454000_spcare-2025-006002v1.36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1248\/bpb.b20-00904","article-title":"Disproportionality Analysis of Safety Signals for a Wide Variety of Opioid-Related Adverse Events in Elderly Patients Using the Japanese Adverse Drug Event Report (JADER) Database","volume":"44","author":"Omoto","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"2026032410201454000_spcare-2025-006002v1.37","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1089\/jpm.2016.0502","article-title":"Methadone-Induced Neurotoxicity in Advanced Cancer: A Case Report","volume":"20","author":"Hoff","year":"2017","journal-title":"J Palliat Med"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-006002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:21:35Z","timestamp":1774372895000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-006002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":37,"alternative-id":["10.1136\/spcare-2025-006002"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-006002","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}